Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict dangerous MS rebound after stopping popular drug

NCT ID NCT05828901

Knowledge-focused Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small, early-terminated study explored whether measuring certain receptors on immune cells could predict disease activity and rebound risk in multiple sclerosis patients taking or stopping ozanimod. Researchers analyzed blood samples from 23 adults with relapsing-remitting MS before and after starting or stopping the drug. The goal was to find a biomarker that could guide safer treatment decisions, but the study's limited size and early stop mean the findings are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ozanimod
What this could lead to
If successful, this could help doctors identify which MS patients are at risk of severe relapse after stopping ozanimod, allowing safer treatment switches.
What could go wrong
The study was terminated early with only 23 participants, so results are limited. It was exploratory, not designed to prove a treatment works, and the biomarker approach may not be reliable in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

23 people

The number who actually took part.

Started

Mar 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with the diagnosis of relapsing remitting MS (RRMS), treated at the Bern University Hospital, who start or stop ozanimod treatment as indicated per clinical routine

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria "On treatment": * Adult patients with RRMS (McDonald criteria 2017) fulfilling the Swiss medic label for ozanimod * Written informed consent Inclusion Criteria "Off treatment": * Adult patients with RRMS (McDonald criteria 2017) who stop ozanimod as indicated in clinical routine. * Written informed consent Exclusion Criteria "On treatment" and "Off treatment": * All vulnerable persons defined by Swiss law including, but not limited to pregnant women, prisoners etc. * Hypersensitivity and allergy against ozanimod or tablet ingredients. * People not understanding the ICF due to mental disabilities. * People with insufficient German or French language skills.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • Neurology department

    Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.